Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest update is out from Kindstar Globalgene Technology, Inc. ( (HK:9960) ).
Kindstar Globalgene Technology, Inc. reported a decrease in revenue by 4.1% for the year ended December 31, 2024, primarily due to changes in settlement models and a slight overall business revenue decline. The company experienced a net loss of RMB60.7 million, attributed to expected credit losses from extended receivable collection periods, fair value losses on fund investments, and the absence of non-recurring government subsidies received in the previous year. Despite these challenges, the gross profit margin improved due to refined product mix and cost control measures.
More about Kindstar Globalgene Technology, Inc.
Kindstar Globalgene Technology, Inc. operates in the medical testing industry, offering a range of services including hematology, neurology, maternity-related, genetic disease, infectious disease, oncology testing, and more. The company is focused on providing comprehensive testing solutions and scientific research services.
YTD Price Performance: 18.64%
Average Trading Volume: 2,301,187
Technical Sentiment Signal: Hold
Current Market Cap: HK$1.46B
For an in-depth examination of 9960 stock, go to TipRanks’ Stock Analysis page.